Recent News

Alectinib Versus Crizotinib in Advanced ALK-Positive Lung Cancer

Who Has Higher Incidence of Lung Cancer in United States: Young Women or Young Men?

Study Results Support Survival Benefit of Atezolizumab-Based Therapy in NSCLC

FDA Expands Approval of Pembrolizumab for First-Line Treatment of NSCLC

Long Noncoding RNAs as Potential Biomarkers in Non–Small Cell Lung Cancer

FDA Accepts Application for First-Line Combination Immunotherapy in Subgroup With NSCLC

ASCO 2018: Safety Analysis of First-Line Nivolumab Plus Ipilimumab for Advanced NSCLC

Projected Lung Cancer Rates in Patients Living With HIV

Combined Effects of FLT3 Ligand and Stereotactic Radiotherapy In Lung Cancer

ASCO 2018: Potential New Standard of Care in Pembrolizumab Combination for Advanced Squamous NSCLC

Expanded Indication for Pemetrexed in Combination Treatment of Metastatic NSCLC

ASCO 2018: Final Overall Survival Results With Dacomitinib vs. Gefitinib in NSCLC

ASCO 2018: Can Genome-Wide Sequencing Assays Detect Early-Stage Lung Cancer?

ASCO 2018: Addition of Immunotherapy to Chemotherapy for Advanced Squamous NSCLC

ASCO 2018: First-Line Pembrolizumab Versus Chemotherapy in Advanced Lung Cancer

Can Radiotherapy Improve Survival in Patients With Metastatic NSCLC?

FDA Accepts New Drug Application for Larotrectinib in Treatment of Certain Solid Tumors

Analysis of Circulating Tumor Cells in Patients With Early Lung Cancer

Second-Line TKI for Leptomeningeal Metastases in Lung Cancer

Atezolizumab Plus Bevacizumab and Chemotherapy in Nonsquamous Lung Cancer

Effect of Cardiac Doses on Survival in NSCLC After Accelerated Radiotherapy

ASCO 2018 Preview: Economic Impact of Genomic Testing Options in Metastatic NSCLC

ASCO 2018 Preview: Low Rates of Lung Cancer Screening Across the United States

Prophylactic Cranial Irradiation and Quality of Life for Patients With NSCLC

Response to Lorlatinib in ALK-Positive Lung Cancer

Pemetrexed Exposure and Adverse Events in NSCLC

FDA Grants Priority Review to Atezolizumab Combination for Metastatic Lung Cancer

AATS 2018: Staging-to-Surgery Time Interval in Stage I NSCLC

FDA Grants Priority Review to Supplemental Biologics License Application for Pembrolizumab in NSCLC

AACR 2018: Tumor Mutational Burden as Biomarker of Response to Immunotherapy in Lung Cancer

ESTRO 37: Concurrent Chemoradiotherapy in Older Patients With Lung Cancer

ELCC 2018: Patient-Reported Outcomes With Durvalumab From PACIFIC Trial

AACR 2018: Nivolumab/Ipilimumab Combination as First-Line Treatment in Advanced NSCLC

ELCC 2018: First-Line Osimertinib in Lung Cancer With Sensitizing EGFR Mutation

AACR 2018: Neoadjuvant Nivolumab for Resectable Lung Cancer

FDA Grants Approval to Osimertinib as First-Line Therapy for Metastatic NSCLC With EGFR Mutations

NCCN Annual Conference 2018: Debut of New Guidelines on Immunotherapy-Related Toxicity

ELCC 2018: Patient-Reported Outcomes With Alectinib Versus Crizotinib in ALK-Positive Lung Cancer

AACR 2018: First-Line Pembrolizumab Plus Chemotherapy for Metastatic Lung Cancer

ELCC 2018: Updated Survival Results With Atezolizumab in the POPLAR Trial

NCCN Annual Conference 2018: Updated Guidelines for NSCLC

FDA Accepts New Drug Application for Dacomitinib to Treat NSCLC With EGFR Mutations

Novel Tissue-Imaging Technology Used for Predicting Recurrence of Lung Cancer

Combination Therapy Plus Maintenance Bevacizumab in First-Line NSCLC

ASCO Endorses ASTRO Guidelines on Stereotactic Body Radiotherapy for NSCLC

Novel Interventional Pulmonology Procedures for Lung Cancer Diagnosis and Treatment

Proton vs. Photon Therapy for Patients With Lung Cancer

Preoperative Exercise and Postoperative Wellness for Patients With Lung Cancer

Interstitial Pneumonitis and Nivolumab Combination Therapy for Lung Cancer

FDA Expands Approval of Durvalumab in Advanced Unresectable Lung Cancer

FDA Grants Priority Review to Lorlatinib in ALK-Positive Lung Cancer

Benefits of Newer Risk-Based Criteria for Lung Cancer Screening

Benefit of Sequential Chemotherapy Followed by Postoperative Radiotherapy for Patients With Lung Cancer

Updated Guidelines for Molecular Testing and Targeted Therapies in Lung Cancer

ASCO-SITC 2018: Study Sheds Light on Immune Microenvironment of Lung Tumors

Smoking History and Molecular Testing for Lung Adenocarcinoma

Path and Evolution of Drug-Resistant Clones in Lung Cancer